The global lung cancer surgery market is poised for transformative growth from 2025 to 2035, driven by the increasing ...
The treatment landscape for HER2-positive NSCLC is rapidly evolving as research continues to reveal the genetic drivers of these tumors. Emerging therapies like Pyrotinib (Jiangsu HengRui Medicine), ...